Preoperative Etanercept Before Inguinal Hernia Surgery

NCT ID: NCT00825344

Last Updated: 2017-10-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 77 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-01-31
• Study Completion Date: 2012-08-31

Brief Summary

Inguinal hernia repair is one of the most frequently performed operations in young men. Persistent pain after inguinal surgery represents a significant cause of disability, occurring in between 15%-35% of cases. In a majority of these patients, their groin pain persisted after a previous hernia repair. The main type of chronic postsurgical pain is neuropathic, caused by injured nerves. One of the principal components in the pathophysiology of postsurgical pain is cytokines, specifically tumor necrosis factor (TNF). In animal studies, injecting TNF inhibitors before nerve injury can reduce pain behaviors and neuropathology. Finding a way to reduce the incidence of postsurgical pain after hernia repair could enhance function, and reduce the need for opioids and other analgesics. The investigators intend to conduct the first randomized, controlled study evaluating whether preemptive administration of a tumor necrosis inhibitor can reduce postoperative pain and opioid consumption after hernia repair. This is important because the degree and intensity of postsurgical pain is a major predictor for the development of chronic postsurgical pain.

Detailed Description

76 patients with an inguinal hernia scheduled for surgical repair will be randomized in a 1:1 ratio to receive either subcutaneous etanercept or saline before skin incision. The study will be double-blind (i.e. neither the surgeon, anesthesiologist, nor the person administering the injection will know which group they were assigned to). Group I will receive 50 mg of subcutaneous etanercept mixed in 1 ml sterile water 90-120" before skin incision. Group II will receive 1 ml of sterile water 90-120" before skin incision. The anesthesia and surgical procedures will be standardized. For the next 24 hours, patients will keep a q4 hour pain diary recording their average pain on a 0-10 numerical rating scale. They will also record the number of Percocet tablets they took. All patients will be seen 1 month after their surgery, where their average pain score, work status, and analgesic intake (if any) will be recorded. Patients will then be followed with a telephone follow-up 3, 6 and 12-months post-procedure, where the same variables will be recorded.

Conditions

Inguinal Hernia; Postoperative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

1

Etanercept 50 mg preoperatively

Group Type: EXPERIMENTAL

Etanercept

Intervention Type: DRUG

50 mg subcutaenous preoperatively

2

Subcutaneous saline preoperatively

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: DRUG

Given subcutaneously preoperatively

Interventions

Etanercept

50 mg subcutaenous preoperatively

Intervention Type: DRUG

Saline

Given subcutaneously preoperatively

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Demonstrable hernia evident using ultrasound, computed tomography, or on physical exam.

2. Pt scheduled for unilateral inguinal hernia repair.

3. Symptoms present for < 6 months.

Exclusion Criteria

1. Non-elective surgery.

2. Previous hernia repair at the same site, or surgery near the site of the hernia.

3. Demyelinating neurological disease.

4. Current or recent (< 6 years) history of substance abuse.

5. Pregnancy, which will be ruled out by a urine pregnancy test in women of childbearing age.

6. Pre-existing untreated psychiatric condition that could preclude an optimal treatment response (e.g. untreated posttraumatic stress disorder).

7. Unstable medical condition (e.g. unstable angina or congestive heart failure or severe).

8. Rheumatoid arthritis, or other systemic conditions that might respond to TNF inhibitors.

9. Pt is immunosuppressed or is taking other drugs (e.g. corticosteroids) that might suppress the immune system.

10. Systemic infection.

11. Any opioid analgesics within 48 hours of skin incision.

12. Any use of tricyclic antidepressants, serotoninin-norepinephrine reuptake inhibitors, or anticonvulsants within 72 hours of skin incision.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Walter Reed Army Medical Center

FED

Sponsor Role: collaborator

John P. Murtha Neuroscience and Pain Institute

UNKNOWN

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Scott Rehrig, MD

Role: STUDY_CHAIR

Walter Reed Army Medical Center

Locations

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

Countries

United States

References

Cheek CM, Black NA, Devlin HB, Kingsnorth AN, Taylor RS, Watkin DF. Groin hernia surgery: a systematic review. Ann R Coll Surg Engl. 1998;80 Suppl 1:S1-80.

Reference Type: BACKGROUND

PMID: 11432408 (View on PubMed)

Franneby U, Sandblom G, Nordin P, Nyren O, Gunnarsson U. Risk factors for long-term pain after hernia surgery. Ann Surg. 2006 Aug;244(2):212-9. doi: 10.1097/01.sla.0000218081.53940.01.

Reference Type: BACKGROUND

PMID: 16858183 (View on PubMed)

Ferzli GS, Edwards E, Al-Khoury G, Hardin R. Postherniorrhaphy groin pain and how to avoid it. Surg Clin North Am. 2008 Feb;88(1):203-16, x-xi. doi: 10.1016/j.suc.2007.10.006.

Reference Type: BACKGROUND

PMID: 18267170 (View on PubMed)

Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004 May 6;361(1-3):184-7. doi: 10.1016/j.neulet.2003.12.007.

Reference Type: BACKGROUND

PMID: 15135924 (View on PubMed)

Other Identifiers

WU08-6987

Identifier Type: -

Identifier Source: org_study_id